Population pharmacokinetics of sirolimus in kidney transplant patients

Objective: To characterize the dose-related pharmacokinetics of the immunosuppressant agent sirolimus (formerly rapamycin) in kidney transplant patients by use of two-stage and nonlinear mixed-effect model population methods. Methods: Patients (n = 36) from three centers (Germany, the United Kingdom, and Sweden) who received steady-state oral doses of cyclosporine (ciclosporin) were assessed after single oral administration of sirolimus at doses of 3, 5, 10, and 15 mg/m(2). Plasma and whole blood sirolimus samples were analyzed by a high-performance liquid chromatographic/mass spectrophotometric method, Simultaneous fitting used biexponential functions with intercept/slope or clearance/volume terms, as well as first-order absorption (k(a)) and a lag-time. Results: The nonlinear mixed-effect model method (P-Pharm) provided a better characterization of sirolimus kinetics, especially for the absorption and distribution phases where fewer data were available per patient, Sirolimus distribution between whole blood and plasma was concentration-independent, with a mean blood/plasma ratio (coefficient of variation) of 30.9 (48.5%), Elimination was not influenced by dose, as shown by estimates of the terminal half-life of 63 hours (27.5%) and apparent oral blood clearance of 8.9 L/hr (38.2%), Sirolimus distribution parameters were influenced by body weight and surface area. Sirolimus was rapidly absorbed, as shown by the absorption lag-time of 0.27 hour (35.1%), and k(a) of 2.77 hr(-1) (48.4%), The concomitant administration of sirolimus and cyclosporine did not reveal any pharmacokinetic interactions. Conclusion: This report provides an initial population pharmacokinetics of sirolimus in kidney transplant recipients receiving cyclosporine concurrently, Sirolimus blood and plasma pharmacokinetics were biexponential and linear for doses from 3 to 15 mg/m(2), No pharmacokinetic interaction was found between sirolimus and cyclosporine.